Impact of Light on Mood

• Sponsor: VA Palo Alto Health Care System (U.S. Fed)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT06027944
• Collaborator: Stanford University (Other)
• Enrollment: 20
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 12
• Patients Per Site Per Month: 1.7

Study Details

Study Description

Brief Summary

The investigators are examining whether the content of a visual scene impacts the antidepressant effects of light or if this impact is solely mediated by the intensity of the light.

Condition or Disease	Intervention/Treatment	Phase
Depression	Other: Light exposure	N/A

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double (Participant, Outcomes Assessor)
• Primary Purpose: Basic Science
• Official Title: More Than Meets the Eye? The Impact of Light on Mood Regulation in Humans
• Anticipated Study Start Date: Oct 1, 2023
• Anticipated Primary Completion Date: Sep 30, 2024
• Anticipated Study Completion Date: Sep 30, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Scene High fidelity scene of nature emitted from a monitor	Other: Light exposure; Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)
Active Comparator: Scrambled scene The same pixels that are used to create the scene in the alternate arm will be randomly scrambled on the monitor	Other: Light exposure; Participants will be exposed to 15 minutes of each arm. They will be exposed twice and a randomized order (1/2/1/2 or 2/1/2/1)

Outcome Measures

Primary Outcome Measures

1. Change in mood [15 minutes]

   Change in subjective mood as recored by the Positive and Negative Affect Schedule (PANAS). The PANAS ranges 10-50 on a positive mood scale (higher = more positive) and 10-50 on a negative mood scale (higher = more negative)

Secondary Outcome Measures

1. Change in fast brain electrical activity [15 minutes]

   Change in the beta power spectrum (12.5-30 Hz) of the electroencephalogram (brain waves, measured in microvolts)

2. Change in systolic blood pressure (SBP) [15 minutes]

   Change in SBP (mm Hg) as measured by finger plethysmography

3. Change in heart rate variability (HRV) [15 minutes]

   Shift in the ratio of the power of low frequency to high frequency components in heart rate variability

4. Change in sympathetic activity [15 minutes]

   Sympathetic activity will be imputed through the galvanic skin response (GSR). Change in skin conductance (the electrical activity on the skin) will be measured in microsiemens

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 60 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Aged 18-60

• Mild depressive symptomatology

Exclusion Criteria:

• No depressive symptomatology

• Severe depressive symptomatology

• Active or unstable medical condition

• Diabetes

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	VA Palo Alto Health Care System	Palo Alto	California	United States	94304

Sponsors and Collaborators

• VA Palo Alto Health Care System
• Stanford University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Jamie M. Zeitzer, Ph.D., Professor, VA Palo Alto Health Care System
• ClinicalTrials.gov Identifier: NCT06027944
• Other Study ID Numbers: IRB-71791
• First Posted: Sep 7, 2023
• Last Update Posted: Sep 7, 2023
• Last Verified: Sep 1, 2023

• Individual Participant Data (IPD) Sharing Statement: Yes
• Plan to Share IPD: Yes
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Depression

Study Results

No Results Posted as of Sep 7, 2023